Week In Review: WuXi PharmaTech Co., Ltd. Sells Stake In CMO Subsidiary; Lists On China OTC Exchange

WuXi PharmaTech sold a 5.55% stake in its chemical CMO operation, SynTheAll Pharma, for $28 million and listed the shares on China's OTC exchange; Sihuan Pharma partnered with CRO Covance Labs, which will help Sihuan coordinate global filings of its novel drugs; Merck Animal Health and China Animal Husbandry Industry signed an MOU to develop vaccines in China; Helsinn of Switzerland out-licensed China rights for an appetite-enhancing drug to the UK's Mundipharma; Solasia Pharma, a Japanese in-licensing company, acquired China-Japan rights to a novel treatment for oral mucositis from Camurus of Sweden; Luye Pharma completed three China Phase I trials of a novel anti-depressant; Hutchison MediPharma of Shanghai reported that fruquintinib met its primary endpoint in China patients with colorectal cancer; Berry Genomics of Beijing received CFDA premarket clearance on its non-invasive prenatal test for birth defects; and Pfizer closed down all of its China vaccine operations after its only approved vaccine in China, Prevenar, did not obtain China license renewal.

Help employers find you! Check out all the jobs and post your resume.